drugset
drugset / Trial / NCT06745804

Study of 68Ga-R10602

NCT06745804 ↗

Phase 1 Completed 27 enrolled Radionetics Oncology
Non-randomizedSequentialOpen-labelDiagnostic

Summary

A phase 1 imaging study of 68Ga-R10602 in hormone-receptor positive breast cancer.

Timeline

Start
2024-12-10
Primary completion
2026-05-04
Completion
2026-05-04

Drugs

EvaluationDrugModalityDoseRoute
Subject 68Ga-R10602 Small molecule — —

Indications

breast adenocarcinoma hormone receptor-positive breast cancer